China NMPA approves subcutaneous lecanemab for early Alzheimer’s
Eisai and Biogen said China’s NMPA approved a lecanemab subcutaneous formulation for initiation treatment in early Alzheimer’s, using a subcutaneous autoinjector (SC-AI).
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.